Mymetics Corporation Share Price

MYMX

US62856A3005

Biotechnology & Medical Research

Market Closed - OTC Markets 02:29:49 29/12/2023 am IST			5-day change	1st Jan Change
3.200 ^USD	+45.45%		+10,66,566.67%	+10,66,566.67%

20/23/20	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/23/18	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Valuation: Mymetics Corporation

Market Cap	4L 4L 4L 3L 6L 4.18Cr 6L 43.52L 17.33L 2.19Cr 16.47L 16.12L 6.94Cr	P/E 2021	-1.86x	P/E 2022	-1.77x
Enterprise Value	7.21Cr 6.47Cr 5.98Cr 5.42Cr 10Cr 686.9Cr 10Cr 72Cr 28Cr 359.44Cr 27Cr 26Cr 1.14TCr	EV / Sales 2021	177x	EV / Sales 2022	78x
Free-Float	99.88%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news: Mymetics Corporation

20/23/20	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/23/18	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
16/23/16	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
11/23/11	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
11/23/11	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
17/23/17	Mymetics Corporation Appoints Marcel B. Rüegg to the Board	CI
29/22/29	Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors	CI
14/22/14	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
11/22/11	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
13/22/13	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
01/22/01	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
31/22/31	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
12/21/12	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI

More news

Press Releases: Mymetics Corporation

11/23/11	MYMETICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
27/23/27	MYMETICS CORP : Other Events (form 8-K)	AQ
09/23/09	MYMETICS CORP : Other Events (form 8-K)	AQ
17/23/17	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
29/22/29	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Mymetics Corporation

Manager	Title	Age	Since
Ronald Hugo Gerard Kempers CEO	Chief Executive Officer	58	19/11/2012

More insiders

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
MYMX Stock

The best tools reserved for subscribers to boost the performance of your investments!

Current year	0		3.2
1 year	0		3.2
3 years	0		4.8
5 years	0		230
10 years	0		380

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MYMETICS CORPORATION	+45.45%	+10,66,566.67%	+10,66,566.67%	+45.45%	45
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	6.35TCr
ARGENX SE	+1.76%	+2.10%	+12.10%	+81.21%	5.45TCr
LONZA GROUP AG	-0.94%	+0.77%	+8.85%	+100.19%	5.36TCr
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+57.51%	4.48TCr
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+100.08%	4.16TCr
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+928.45%	3.99TCr
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	3.25TCr
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	2.67TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	2.34TCr
Average	+8.63%	-0.38%	+1,06,703.41%	+150.87%	3.8TCr
Weighted average by Cap.	+3.21%	-0.29%	+47.35%	+161.19%

	2021	2022
Net sales	4L 4L 4L 3L 6L 4.1Cr 6L 42.65L 16.99L 2.14Cr 16.14L 15.8L 6.8Cr	10.28L 9L 9L 8L 14.43L 9.79Cr 14.6L 1.02Cr 40.61L 5.12Cr 38.58L 37.76L 16Cr
Net income	-47.3L -42.44L -39.24L -35.53L -66.39L -45Cr -67.19L -4.69Cr -1.87Cr -24Cr -1.77Cr -1.74Cr -75Cr	-48.05L -43.11L -39.86L -36.1L -67.44L -46Cr -68.26L -4.77Cr -1.9Cr -24Cr -1.8Cr -1.77Cr -76Cr
Net Debt	6.71Cr 6.02Cr 5.57Cr 5.04Cr 9.42Cr 639.07Cr 9.53Cr 67Cr 27Cr 334.41Cr 25Cr 25Cr 1.06TCr	7.17Cr 6.43Cr 5.95Cr 5.39Cr 10Cr 682.72Cr 10Cr 71Cr 28Cr 357.26Cr 27Cr 26Cr 1.13TCr

Mymetics Corporation Share Price

Stocks

MYMX

US62856A3005

Biotechnology & Medical Research

Valuation: Mymetics Corporation

Latest news: Mymetics Corporation

Press Releases: Mymetics Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Mymetics Corporation

Bio Therapeutic Drugs

Financials

Company Profile

1 day	+45.45%
1 week	+10,66,566.67%
Current month	+10,66,566.67%
1 month	+10,66,566.67%
3 months	+10,66,566.67%
6 months	+10,66,566.67%
Current year	+10,66,566.67%